NCT04037748View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

September 11, 2019

Study Completion Date

September 11, 2019

Conditions
Healthy
Interventions
DRUG

Puran T4®

Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.

DRUG

Eutirox®

Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.

Trial Locations (1)

Unknown

Instituto de Ciências Farmacêuticas de Estudos e Pesquisas, Aparecida de Goiânia

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04037748 - Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form | Biotech Hunter | Biotech Hunter